Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RH5.1/Matrix-M Malaria Vaccine Phase I
NCT06141057Phase 1Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RH5.1 in malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Solicited Reactogenicity, Unsolicited Adverse Events and 2 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
RH5.1
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06141057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141057.